Steve Arkinstall, Revitope CEO

Mass­a­chu­setts biotech Re­vi­tope scores first col­lab­o­ra­tion thanks to dual-en­gag­ing T cell plat­form

Re­vi­tope On­col­o­gy be­gan 2020 hope­ful that its can­cer im­munol­o­gy plat­form would be fi­nal­ly ready to flour­ish. On Mon­day night, that plat­form nabbed the biotech its first col­lab­o­ra­tion.

The Mass­a­chu­setts-based com­pa­ny has agreed to a li­cens­ing agree­ment with Shang­hai-based Jun­shi Bio­sciences in which Re­vi­tope can re­ceive up to $160 mil­lion in de­vel­op­ment and com­mer­cial mile­stones, plus roy­al­ties. In ad­di­tion, Jun­shi will make a di­rect eq­ui­ty in­vest­ment of $10 mil­lion, equal to 9.99% of Re­vi­tope shares, as the two com­pa­nies work to de­vel­op a dual-anti­gen tar­get­ing can­cer ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.